Loading the section…
The price of IDEAYA Biosciences, Inc. (IDYA) on October 9, 2026 is 36.11 USD, +0.14% on the day. Over 52 weeks the stock traded between 26.05 USD and 42.68 USD; the price now sits 60% of the way up that range. Over the past year the price changed by +34.54%. Market capitalization is 3.17 billion USD, rank 55 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +34.89 %
IDEAYA Biosciences, Inc. trades on Nasdaq under the ticker IDYA. The company belongs to the Health care sector. The trading history on this page starts on 23 May 2019.
Over the past 52 weeks IDYA has traded between 26.05 $ and 42.68 $. As of 9 October 2026 the price stood 60.49 % of the way from the 52-week low to the high.
Over one year IDYA shares rose 34.54 %; over six months they rose 18.39 %. Volatility over 90 days is 47.25 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 14.5, above the sector median of 4.0. Price to book is 3.4, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 35.94 | 36.72 | 35.94 | 36.11 | 698,900 |
| 8 October 2026 | 35.85 | 36.32 | 35.10 | 36.06 | 548,700 |
| 7 October 2026 | 36.19 | 36.97 | 36.00 | 36.26 | 552,100 |
| 6 October 2026 | 38.23 | 38.57 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
IDEAYA Biosciences, Inc. (IDYA) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 218.7m $, net income was -140.1m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080, US
IDEAYA Biosciences, Inc. reported revenue of 219M $ and a net loss of 140M $ over the last four quarters. Revenue changed by +3,024.43 % year over year. Earnings per share are −1.57 $. Market capitalisation is 3.2B $.
IDYA has a return on equity of −14.94 %, above the sector median of −41.68 %. Return on assets is −13.59 %, above the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 36.11 |
| 36.63 |
| 802,500 |
| 5 October 2026 | 37.57 | 38.26 | 37.04 | 38.06 | 658,000 |
| 2 October 2026 | 38.52 | 38.54 | 37.00 | 37.36 | 579,000 |
| 1 October 2026 | 38.34 | 39.32 | 37.62 | 37.81 | 712,300 |
| 30 September 2026 | 38.11 | 39.39 | 37.76 | 38.42 | 1M |
| 29 September 2026 | 38.14 | 38.43 | 37.20 | 37.86 | 815,400 |
| 28 September 2026 | 36.26 | 38.73 | 36.10 | 38.22 | 1M |
| 25 September 2026 | 36.74 | 36.99 | 36.16 | 36.69 | 487,300 |
| 24 September 2026 | 37.46 | 37.78 | 35.59 | 36.74 | 1M |
| 23 September 2026 | 39.74 | 39.88 | 37.00 | 37.46 | 2M |
| 22 September 2026 | 39.11 | 40.00 | 38.93 | 39.71 | 745,800 |
| 21 September 2026 | 38.71 | 39.00 | 37.99 | 38.86 | 571,100 |
| 18 September 2026 | 38.88 | 39.25 | 38.15 | 38.41 | 2M |
| 17 September 2026 | 38.61 | 39.47 | 38.53 | 38.61 | 757,800 |
| 16 September 2026 | 37.71 | 38.46 | 37.24 | 37.73 | 639,800 |
| 15 September 2026 | 37.88 | 38.24 | 37.13 | 37.66 | 654,200 |
| 14 September 2026 | 38.50 | 39.33 | 37.74 | 38.03 | 524,700 |